Even if they’re not robots in the same sense that your or I might think of, the tiny molecules that can automate their tasks are quite useful. Both Douglas and Margarkar are working on nanorobots that can sense where they are, and deliver a drug at the right location. So if a bot is carrying a drug that is meant to kill liver-cancer cells, it would also be outfitted with a sensor to tell when it encounters those cells.

This targeted drug delivery has all sorts of upsides: You’re not dousing the body in poison hoping it reaches the thing the poison is meant to kill, for example. But it’s not easy to design. In fact, the field of nanorobotics has encountered a whole lot of challenges since its invention, ones that hold us back from the promise of those predictors and science-fiction writers.

One challenge when it comes to synthesizing nanorobots is that it takes a lot of work to actually make enough material to test your ideas on. “It’s a matter of all the practical annoying steps of actually doing it,” Douglas says. “The big thing that half of my lab is stuck on is making enough material that we can test. We could do a very small amount of material, we synthesize the DNA and we run a few experiments and show in a petri dish and say ‘Hey this looks promising. We made millions of little things and some of them do what we expect.’” But the next step in that process means picking those promising things up, and testing them on a lot more material. “We need 100,000 times that much material, which would bankrupt the entire lab. So we have to invent a new way to make it, so that takes a couple of years. And then before you know it five years have gone by.”

Then, once you make enough material, and have a promising candidate, Margarkar says that sometimes there’s not a great system in place to test your idea. Pharmaceutical studies are designed to look for results in the end organ or illness. Take a drug for liver cancer: If the drug reduces the liver cancer, it is successful. But when it comes to nanoparticle delivery, researchers also want to be able to figure out if the process, the actual movement from injection through the body to the liver cells, works the way they designed it to. If it fails, did it fail to detect the cells? Or did it fail to release the drug when it did detect the cells? Or did the drug itself just not work to kill the cancer? The answers to these questions are key, and Margarkar says that for a long time there wasn’t a good way to figure them out. Now, researchers have started using computer models and scans to predict and then track the nanorobots on their whole trip.

Then, once you have a delivery system that works, and a drug that works, researchers have to tackle the FDA. Getting nanoparticle robots approved isn’t necessarily the issue, but getting the combination of drug and robot approved can be. Margarkar says that sometimes, even if both the nanoparticle and the drug have both been proven safe individually, the FDA may require the combination to be run through the entire approval process again. “So you’re testing it again in the lab, then on animals, then on people. From the moment you enter that process it can take eight to 10 years to finish,” he says.